{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:18Z","timestamp":1793805918506,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jocn.2026.112153","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:24:23Z","timestamp":1781666663000},"page":"112153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Plasma concentration threshold and risk factors for amantadine-induced central nervous system toxicity in Parkinson\u2019s disease"],"prefix":"10.1016","volume":"152","author":[{"given":"Masahiro","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Miyaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Ihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2026.112153_b0005","article-title":"Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders","volume":"2016","author":"Lee","year":"2016","journal-title":"Schizophr Res Treat"},{"key":"10.1016\/j.jocn.2026.112153_b0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mdc3.12595","article-title":"Parkinson's patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102","volume":"5","author":"Isaacson","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.jocn.2026.112153_b0015","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/cts.12684","article-title":"Effect of repeated intravenous amantadine infusions in patients with Parkinson's disease: an open-label pilot study","volume":"12","author":"Khlebtovsky","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jocn.2026.112153_b0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mds.70120","article-title":"Effect on dyskinesia of the early combination of amantadine with levodopa therapy in Parkinson\u2019s disease (PREMANDYSK): a randomized, placebo-controlled study","volume":"41","author":"Rascol","year":"2026","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2026.112153_b0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40120-019-0144-1","article-title":"Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies","volume":"8","author":"deVries","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1016\/j.jocn.2026.112153_b0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40263-019-00651-1","article-title":"Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets","volume":"33","author":"deVries","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jocn.2026.112153_b0035","article-title":"Amantadine-associated delirium in patients with maintenance dialysis: insomnia-associated recovery and uneven seasonal distribution","volume":"102","author":"Li","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jocn.2026.112153_b0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/clinpract13040075","article-title":"Myoclonus secondary to amantadine: case report and literature review","volume":"13","author":"Rissardo","year":"2023","journal-title":"Clin Pract"},{"key":"10.1016\/j.jocn.2026.112153_b0045","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.21873\/invivo.13669","article-title":"Central nervous system adverse reactions to amantadine intoxication: a case report and analysis of JADER","volume":"38","author":"Ide","year":"2024","journal-title":"In Vivo"},{"key":"10.1016\/j.jocn.2026.112153_b0050","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.parkreldis.2008.08.005","article-title":"Plasma amantadine concentrations in patients with Parkinson\u2019s disease","volume":"15","author":"Nishikawa","year":"2009","journal-title":"Parkinson Relat Disord"},{"key":"10.1016\/j.jocn.2026.112153_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2026.112153_b0060","first-page":"31","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:25:53Z","timestamp":1793802353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"alternative-id":["S0967586826003048"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112153","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma concentration threshold and risk factors for amantadine-induced central nervous system toxicity in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112153"}}